New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
16:31 EDTDEPODepomed files patent infringement suit against Purdue Pharma
Depomed disclosed in a regulatory filing that on January 29, Depomed filed a complaint in the United States District Court for the District of New Jersey against Purdue Pharma and affiliated companies for infringement of U.S. Patent Nos. 6,340,475; 6,635,280; and 6,723,340. The complaint alleges infringement of the Depomed patents arising from Purdue’s commercialization of OxyContin in the United States. The Depomed patents relate to Depomed’s Acuform drug delivery technology. U.S. Patent Nos. 6,340,475 and 6,635,280 will expire in 2016, and U.S. Patent No. 6,723,340 will expire in 2021.
News For DEPO From The Last 14 Days
Check below for free stories on DEPO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
11:18 EDTDEPODepomed announces favorable ruling in Gralise case
Subscribe for More Information
10:32 EDTDEPODepomed higher after favorable ruling in Gralise case
Subscribe for More Information
August 8, 2014
15:26 EDTDEPOPDL BioPharma announces delay in 10-Q filing, postpones Q2 earnings call
PDL BioPharma (PDLI) confirmed that the company has filed a Form 12b-25 Notification of Late Filing with the SEC allowing for a five-day extension to file its Quarterly Report on Form 10-Q for the period ended June 30. The company has not yet finalized its financial statements for the quarter ended June 30 due to additional time necessary to address SEC comments and finalize its review related to a change in the accounting treatment of the acquisition of Depomed (DEPO) royalty rights. As previously disclosed, PDL was asked by the SEC to support its position and explain why this transaction was accounted for as the acquisition of intangible assets as opposed to that of financial assets. As a result of the delay in filing the quarterly report, PDL has postponed its second quarter earnings release call, originally scheduled for Monday, August 11, until further notice.
14:54 EDTDEPOPDL BioPharma says concluding talks with SEC on Depomed deal accounting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use